|
注册号: Registration number: |
ChiCTR2500113296 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-26 18:17:22 |
|
注册时间: Date of Registration: |
2025-11-26 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
口腔菌群和NLRP3炎症复合体与结直肠息肉的相关性研究 |
|
Public title: |
Relationship among oral microbiome and NLRP3 inflammatome and colorectal polyps |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
口腔菌群和NLRP3炎症复合体与结直肠息肉的相关性研究 |
|
Scientific title: |
Relationship among oral microbiome and NLRP3 inflammatome and colorectal polyps |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张丽敏 |
研究负责人: |
张丽敏 |
|
Applicant: |
Zhang Limin |
Study leader: |
Zhang Limin |
|
申请注册联系人电话: Applicant telephone: |
+86 21 24289296 |
研究负责人电话:
Study leader's |
+86 21 24289296 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
minlizhang1993@126.com |
研究负责人电子邮件: Study leader's E-mail: |
minlizhang1993@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市闵行区鹤庆路801号 |
研究负责人通讯地址: |
上海市闵行区鹤庆路801号 |
|
Applicant address: |
No. 801, Heqing Road, Minhang District, Shanghai |
Study leader's address: |
No. 801, Heqing Road, Minhang District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属上海市第五人民医院 |
||
|
Applicant's institution: |
Shanghai Fifth People’s Hospital, Fudan University |
||
|
研究负责人所在单位: |
上海市第五人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Fifth Peoople's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2021)伦审第(127)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属上海市第五人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Shanghai Fifth People's Hospital Affiliated to Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-09-20 00:00:00 | ||
|
伦理委员会联系人: |
钱少霞 |
||
|
Contact Name of the ethic committee: |
Qian Shaoxia |
||
|
伦理委员会联系地址: |
上海市闵行区鹤庆路801号 |
||
|
Contact Address of the ethic committee: |
No. 801, Heqing Road, Minhang District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 24289466 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
18656362028@163.com |
|
研究实施负责(组长)单位: |
上海市第五人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Fifth Peoople's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市闵行区鹤庆路801号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 801, Heqing Road, Minhang District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
闵行区自然科学研究课题 |
||||||||||||||||||||||
|
Source(s) of funding: |
Minhang District natural science research project |
||||||||||||||||||||||
|
研究疾病: |
结直肠息肉 |
||||||||||||||||||||||
|
Target disease: |
Colorectal polyp |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
NLRP3炎症复合体可能与口腔疾病或肠息肉密切相关,但关于口腔和肠道菌群、NLRP3炎症复合体、结直肠息肉三者之间的相关性正式尚未见报道。因此,本研究拟采用病例对照研究,通过检测结直肠息肉患者和健康对照者的口腔和肠道菌群以及外周静脉血和肠道组织中NLRP3、ASC、Caspase-1、IL-1β、IL-18的表达情况,建立口腔菌群和肠道菌群联合诊断结直肠息肉的模型,分析口腔和肠道特异性菌群与宿主炎症状态的相关性,探索口腔和肠道菌群、NLRP3炎症复合体、结直肠息肉三者之间的相关性(两两之间的相关性),以期从口腔和肠道微生物以及宿主免疫炎症反应层面,为结直肠息肉的诊断、预后评估提供新的生物标志物,并为临床防治提供新的靶向治疗策略,积极防止结直肠息肉癌变的发生发展,目前国内外少见研究报道。本研究具有显著的临床实践意义和社会经济效益,其研究成果能够很好的进行临床转化,一方面,某些口腔和肠道菌群可作为结直肠息肉患者的辅助诊断指标,发现有特异性菌群变化时及时建议患者行消化系统的检查和评估,以期结直肠息肉患者能尽早诊治。另一方面,对已确诊的结直肠息肉患者应加强口腔卫生宣教,使之掌握充足的口腔健康知识和行为,定期进行口腔检查,降低口腔致病菌群,积极采用多学科综合预防和治疗的方法,继而提高患者全身的功能状态和生活质 量。 |
||||||||||||||||||||||
|
Objectives of Study: |
In this study, a case-control study was intended to establish a model for the combined diagnosis of colorectal polyps by detecting the expressions of oral and intestinal flora, ASC, Caspase-1, IL-1β and IL-18 in patients with colorectal polyps and healthy controls, as well as peripheral venous blood and intestinal tissue. To analyze the correlation between oral and intestinal specific flora and host inflammatory status, and explore the correlation between oral and intestinal flora, NLRP3 inflammatory complex, and colorectal polyps (pin-pin-two correlation), with a view to providing new biomarkers for the diagnosis and prognosis assessment of colorectal polyps from the perspective of oral and intestinal microorganisms and host immune inflammatory response. It also provides a new targeted treatment strategy for clinical prevention and treatment, and actively prevents the occurrence and development of colorectal polyp canceration. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.患者拒绝参加此项目; 2.患者认知障碍,不能配合研究者; 3.患者诊断为家族性腺瘤性息肉病或遗传性非息肉性结直肠癌,或家系中 有明显的家族遗传倾向者,合并其他消化系统疾病、肛肠疾病者; 4.感染性疾病;如呼吸道、消化道、泌尿系、生殖系统急慢性感染等; 5.有系统性疾病史者:心脑肝肾等重要脏器严重病变者,如器官功能障 碍:如肝硬化、肾衰竭等(有严重心、肝、肾功能不全者); 6.免疫性疾病:如结缔组织病、类风湿关节炎等; 7.血液系统疾病(有原发性血脂异常疾病,或近3个月服用调脂药); 8.恶性肿瘤,接受过放化疗治疗者; 9.BMI小于18.5kg/m^2或BMI大于32kg/m^2 或严重营养不良; 10.合并有糖尿病(含1型及2型)、痛风等慢性代谢性疾病; 11.既往胃肠道手术史,既往因息肉或肿瘤有肠道手术史的患者; 12.妊娠期和哺乳期妇女; 13.无牙颌的患者; 14.在过去6个月有牙周治疗史的患者; 15.口内有固定矫治器的患者; 16.近1个月内使用益生菌、微生态活菌制剂、抗生素、二甲双胍、质子泵抑 制剂、黄连素、导泻剂。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. The patient refused to participate in this project. 2. The patient has cognitive impairment and is unable to cooperate with the researcher. 3. Patients diagnosed with familial adenomatous polyposis or hereditary non-polyposis colorectal cancer, or those with a clear familial genetic predisposition in the family, and those with other digestive system diseases or anorectal diseases; 4. Infectious diseases; Such as acute and chronic infections of the respiratory tract, digestive tract, urinary system, reproductive system, etc. 5. Those with a history of systemic diseases: Those with severe lesions in vital organs such as the heart, brain, liver and kidneys, such as organ dysfunction: such as liver cirrhosis, renal failure, etc. (those with severe insufficiency of heart, liver and kidney functions); 6. Immune diseases: such as connective tissue diseases, rheumatoid arthritis, etc. 7. Blood system diseases (with primary dyslipidemia or taking lipid-regulating drugs in the past 3 months); 8. Malignant tumors, those who have received radiotherapy and chemotherapy treatment; 9.BMI less than 18.5kg/m ² or BMI greater than 32kg/m ² or severe malnutrition; 10. Complicated with chronic metabolic diseases such as diabetes (including type 1 and type 2) and gout; 11. Patients with a history of gastrointestinal surgery or intestinal surgery due to polyps or tumors in the past; 12. Pregnant and lactating women; 13. Patients with edentulous jaws; 14. Patients who have had periodontal treatment in the past six months; 15. Patients with fixed orthodontic appliances in their mouths; 16. Within the past month, probiotics, microecological live bacteria preparations, antibiotics, metformin, proton pump inhibitors, berberine, and laxatives have been used. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-05-01 00:00:00至 To 2025-12-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-04-05 00:00:00 至 To 2025-12-27 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the end of the study, it was shared by ResMan (www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF;EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF;EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |